[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fujian Maternity and Child Health Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100537321","protein-molecular-characteristics-and-prognosis-of-cervical-neuroendocrine-tumors-100537321",false,"NCT06276309","Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors","Inclusion Criteria:\n\n1. Patients diagnosed with cervical neuroendocrine carcinoma by histopathology\n2. Clinical data were complete\n\nExclusion Criteria:\n\n1. Patients who are not being treated in our hospital\n2. Patients with lack of follow-up data, unable to obtain survival information\n3. Patients call to refuse to participate in this project\n4. The quality of paraffin specimens can not meet the requirements of proteome concentration determination","FEMALE",{"count":17,"type":18},300,"ESTIMATED","OBSERVATIONAL","The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.",[22,23,24,25,26],"Neuroendocrine Neoplasm","China","Women","Cervical Cancer","Cervical Lesion","RECRUITING","2024-09-12",{"date":30,"type":31},"2024-09-19","ACTUAL",{"date":33,"type":31},"2024-02-01",{"date":35,"type":18},"2025-02-28",{"name":37,"class":38},"Fujian Maternity and Child Health Hospital","OTHER",9,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100460935","effect-of-hpv-integration-on-prognosis-of-young-women-with-cin2-in-china-100460935","NCT05282095","Effect of HPV Integration on Prognosis of Young Women With CIN2 in China","Effect of HPV Integration on Prognosis of Young Women With CIN2 in China: A Multi-center Cohort Study in China","Inclusion Criteria:\n\n* Female, 18 years of age or older and 45 years of age or younger, with a desire to conceive;\n* Diagnosed with HSIL (CIN2) or HSIL (CIN2-3) via cervical tissue biopsy within the past 3 months, and has not undergone cervical surgery, physical, or medication treatment;\n* The lesion area under colposcopy is less than 50% of the total cervical area within the past 3 months;\n* Plans for 12-month follow-up observation for CIN2, with no surgical, physical, or medication treatment if the disease does not progress;\n* Understands and voluntarily agrees to participate in the 12-month follow-up of this study, and signs the informed consent form.\n\nExclusion Criteria:\n\n* Cervical status at the time of enrollment as determined by colposcopy within the past three months is Type III transformation zone;\n* Pregnant or lactating;\n* History of malignant reproductive tract tumors;\n* History of hysterectomy, cervical surgery, or pelvic radiation therapy;\n* Physical therapy to the cervix within 24 months prior to enrollment;\n* The subject has a severe immune system disease that is active;\n* Long-term use of contraceptives within 12 months prior to enrollment;\n* Vaginal medication or irrigation within 72 hours prior to sampling (can re-enroll for sampling 3 days after cessation);\n* Sexual intercourse within 24 hours prior to sampling (can re-enroll for sampling 24 hours after cessation);\n* Received treatment for genital tract infections, HPV, or other STD pathogens within the past month (can re-enroll one month after cessation of treatment);\n* Used antibiotics or vaginal microecological improvement products within the past month (can re-enroll one month after cessation of use);","45 Years",{"count":17,"type":18},"Clinically, cervical precancerous lesion is one of the important diseases that endanger the life safety and fertility of young women. Women with histopathologically confirmed CIN2 need regular HPV, cervical cytology, and colposcopic biopsy if necessary to assess the outcome and progression of the disease. In this study, we intend to visit Fujian Maternal and Child Health Hospital, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science \\& Technology and other hospitals, including 300 CIN2 participants aged 45 and below diagnosed by histopathology, and collect the remaining cervical secretions and cervical exfoliated cell samples after clinical examination, even if you do not participate in this clinical study. In clinical diagnosis, treatment and follow-up, it is also necessary to collect the above specimens for relevant medical tests. Therefore, it is of great clinical and scientific significance to explore the role of HPV integrated detection in predicting the prognosis of young women with CIN2.",[51,52,53,54],"Cervical Intraepithelial Neoplasia","HPV Infection","Virus Integration","HSIL, High Grade Squamous Intraepithelial Lesions",{"date":30,"type":31},{"date":57,"type":31},"2022-06-01",{"date":59,"type":18},"2026-05-31",{"name":37,"class":38},20,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":15,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100526638","two-domestic-hpv-vaccines-and-imported-hpv-vaccines-in-women-aged-13-14-years-study-on-immunogenicity-100526638","NCT06137352","Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity","Two Domestic HPV Vaccines (Wozehui ® and Cecolin ®) and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity：A Multi-center Cohort Study in China","Inclusion Criteria:\n\n* Participants who have completed all procedures of domestic bivalent HPV vaccine or imported HPV vaccine and are 30-60 days from the last dose of vaccination at the time of enrollment;\n* The participants are between 13-14 years old at the time of the first dose of domestic or imported HPV vaccination;\n* The participant himself\u002Fherself and his\u002Fher guardian are able to provide proof of legal identity;\n* The participant and his\u002Fher guardian are capable of understanding and signing the informed consent form;\n* Participants are willing to complete study-related follow-up visits and blood collection as required by the protocol.\n\nExclusion Criteria:\n\n* Participants who have received other marketed HPV vaccines, or who have participated in clinical studies of HPV vaccines, or who have participated in clinical studies of other vaccines within the last 6 months;\n* Participants with congenital malformations, developmental disorders, genetic defects, and severe malnutrition that are severe or cause damage to vital organs;\n* Participants with a history of epilepsy, psychosis, and major depression requiring medication, convulsions or seizures or a family history of psychosis;\n* Participants who are immune compromised or have been diagnosed with congenital or acquired immunodeficiency, Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, Systemic Lupus Erythematosus (SLE), Rheumatoid - - Arthritis, Juvenile Rheumatoid Arthritis (JRA), Inflammatory Bowel Disease (IBD), or other autoimmune disease, subjects who have received immunosuppressive therapy within the past 6 months;\n* Absence of spleen, functional absence of spleen, and subjects with any condition resulting in absence of spleen or splenectomy;\n* Subjects with physician-diagnosed coagulation abnormalities (e.g., coagulation factor deficiencies, coagulopathies, platelet abnormalities) or significant bruising or coagulation disorders;\n* Participants who, in the judgment of the investigator, have any other factors that make them unsuitable for participation in a clinical trials.",true,"13 Years","14 Years",{"count":73,"type":18},3000,"This is a multi-center, open, prospective cohort study that aims to investigate the immunogenicity and immune persistence of two different domestically produced bivalent HPV vaccines compared with an imported HPV vaccine in women aged 13-14 years. A total of 3,000 subjects who have completed 2 doses of the domestic bivalent HPV vaccine and 3 doses of the imported HPV vaccine will be recruited from Fujian Maternal and Child Health Hospital as the initiator of the study, and will be recruited from a number of healthcare institutions nationwide. Of these, 1,000 subjects were vaccinated with the domestic bivalent HPV vaccine (Wozehui), 1,000 subjects were vaccinated with the domestic bivalent HPV vaccine (Cecolin), and 1,000 subjects were vaccinated with the imported HPV vaccine. Each subject was enrolled within 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and a total of two follow-up visits were conducted 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine. In response to the WHO Cervical Cancer Elimination Strategy, domestic bivalent HPV vaccine has been offered free of charge to adolescent females aged 13-14 years, but there is still a lack of evidence comparing the antibody titer levels of domestic HPV vaccine and imported HPV vaccine in younger females. Therefore, we conducted the present immunogenicity study to explore the immunogenicity and immune persistence after vaccination with domestic bivalent HPV vaccine versus imported HPV vaccine in this age group of females.",[52,76,77],"HPV Vaccine","Cervical Cancer Prevention","NOT_YET_RECRUITING","2023-11-16",{"date":81,"type":31},"2023-11-18",{"date":83,"type":18},"2023-12-15",{"date":85,"type":18},"2026-12-31",{"name":37,"class":38},1,""]